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Introduction
Cystic fibrosis (CF) is a monogenic autosomal disease caused by mutations in the cystic fibrosis transmem-
brane conductance regulator (CFTR). Loss of  CFTR protein function disrupts bicarbonate, salt, and fluid flux 
across epithelial-lined tissues and impairs the physiology of  numerous organs. As greater numbers of  individ-
uals with CF live longer, the prevalence of  CF-related diabetes (CFRD) has increased dramatically, affecting 
approximately 35% of adults with CF (1). Importantly, CFRD exacerbates CF-related complications and is 
associated with increased mortality (2, 3). CFRD is recognized as a form of type 3c (pancreatogenic) diabe-
tes but is often regarded as a distinct clinical entity (2, 4), as CFRD displays features of  both type 1 diabetes 
(T1D) and type 2 diabetes (T2D) that occur in the setting of  pancreatic insufficiency, multiorgan dysfunction, 
chronic infection, malabsorption, malnutrition, and varying degrees of  insulin resistance (5–10).
Recently, loss of  CFTR function in cell lines and cultured rodent/ferret and human islets has been 
reported to impair insulin secretion (11–14) and augment glucagon secretion (15, 16), suggesting that loss 
of  CFTR function in islet endocrine cells contributes to CFRD via intrinsic disruption of  β and α cell stim-
ulus-secretion coupling. Conversely, studies of  humans and CF animal models have suggested that CFRD 
results from CF-induced pancreatic autolysis, inflammation, and reduction of  β cell mass (17–20) causing 
insufficient islet hormone secretion (20–27). These findings are supported by an association among CFRD, 
Cystic fibrosis–related (CF-related) diabetes (CFRD) is an increasingly common and devastating 
comorbidity of CF, affecting approximately 35% of adults with CF. However, the underlying causes 
of CFRD are unclear. Here, we examined cystic fibrosis transmembrane conductance regulator 
(CFTR) islet expression and whether the CFTR participates in islet endocrine cell function using 
murine models of β cell CFTR deletion and normal and CF human pancreas and islets. Specific 
deletion of CFTR from murine β cells did not affect β cell function. In human islets, CFTR mRNA 
was minimally expressed, and CFTR protein and electrical activity were not detected. Isolated CF/
CFRD islets demonstrated appropriate insulin and glucagon secretion, with few changes in key 
islet-regulatory transcripts. Furthermore, approximately 65% of β cell area was lost in CF donors, 
compounded by pancreatic remodeling and immune infiltration of the islet. These results indicate 
that CFRD is caused by β cell loss and intraislet inflammation in the setting of a complex pleiotropic 
disease and not by intrinsic islet dysfunction from CFTR mutation.
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exocrine disease severity, and pancreatic insufficiency (3, 28). Thus, the relative contributions of  intrinsic 
islet cell dysfunction and islet loss to the pathogenesis of  CFRD remain unclear.
To elucidate the underlying causes of  CFRD and the role of  CFTR in islet cell function, we generated 
acute and chronic models of  β cell–specific CFTR deletion and investigated the effect(s) of  CFTR loss on 
glucose tolerance and/or β cell function. As human islets possess a number of  unique and important differ-
ences relative to rodent islets (29–34) and knowledge regarding CFTR expression and function in human 
Figure 1. β Cell CFTR deletion did not alter murine oral glucose tolerance or islet insulin secretion. (A) Murine models created to excise Cftr exon 11 from β 
cells in an inducible fashion (β Δ11) or from the pancreas with constitutive Cre action (Panc Δ11). (B) Experimental timeline of murine models. Analyses included 
oral glucose tolerance testing (OGTT) on conscious animals, insulin secretion assays, and RNA sequencing of whole islets. OGTT of (C) male β cell–specific/
inducible mice prior to (Pre-Tx; n = 46) and after treatment with vehicle (V; n = 17) or tamoxifen (β 
Δ11; n = 23) and (D) pancreatic/constitutive mice homozygous 
for the Cftr wt allele (Panc wt; n = 8) and mice homozygous for the Cftr FL11 allele (Panc Δ11; n = 11). Insulin secretion from isolated islets incubated in medium con-
taining (E and H) 5.6 mM glucose (5.6 G), 16.7 mM glucose (16.7 G), or (F and I) 16.7 mM glucose and 100 μM 3-isobutyl-1-methylxanthine (16.7 G + IBMX), and 
(G and J) islet insulin content from β cell–specific/inducible mice (E–G: V, n = 8, 5 male, 3 female; β Δ11, n = 9, 6 male, 3 female) and pancreatic/constitutive mice 
(H–J: Panc wt, n = 13, 6 male, 7 female; Panc Δ11, n = 20, 10 male, 10 female). We observed slight differences in glucose-stimulated insulin secretion, cAMP-po-
tentiated GSIS, and islet insulin content between the control animals of the β Δ11 and Panc Δ11 models. However, the control animals were individualized for each 
model and differ in the type of Cre recombinase expressed as well as the expression promotor (A). Red represents the β cell–specific/inducible model (β Δ11), 
blue the pancreatic constitutive model (Panc Δ11). Data represent mean ± SEM. No statistical significance (P < 0.05) was observed in OGTT AUC, insulin secre-
tion, or insulin content in either model. Statistical data were calculated with 1-way ANOVA (C and D) or unpaired 2-tailed Student’s t test (E–J).
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islets is limited (11, 15, 35), we examined CFTR mRNA and protein expression in human islet endocrine 
cells, whether CFTR regulates human islet insulin secretion, and the hormone secretory profile and tran-
scriptome of  human CF islets. Our studies indicate that the CFTR does not intrinsically regulate α or β cell 
function and that the etiology of  CFRD is largely dependent on islet loss and intraislet inflammation in the 
setting of  a complex and progressive multiorgan disease.
Results
Deletion of  β cell CFTR did not affect glucose tolerance. To directly test whether CFTR intrinsically regulates 
β cell insulin secretion, we created two murine models of  β cell CFTR deletion (Figure 1A) and assessed 
glucose tolerance, islet insulin secretion, and islet gene expression (Figure 1B). A β cell–specific/inducible 
CFTR-knockout (β Δ11) mouse model allowed us to investigate the effects of  acute β cell CFTR deletion in 
adult mice. We also generated a pancreatic/constitutive CFTR-knockout (Panc Δ11) mouse to investigate the 
effect of  CFTR deletion in pancreatic cells during development and persistent deletion in adult β cells. Impor-
tantly, we have shown that excision of  Cftr exon 11 renders the CFTR electrically silent (36). Oral glucose 
tolerance testing (OGTT) to assess whole-animal glucose handling was similar to controls in both β Δ11 (Figure 
1C; Supplemental Figure 1, B–F; and Supplemental Figure 2, A–F; supplemental material available online 
with this article; https://doi.org/10.1172/jci.insight.98240DS1) and Panc Δ11 (Figure 1D and Supplemental 
Figure 1, H–L) male and female animals. These results indicate that deletion of  CFTR from murine β cells 
did not affect glucose homeostasis.
Insulin secretion was not affected by CFTR β cell deletion. To investigate whether β cell CFTR deletion 
caused an insulin secretory defect that was not detected by OGTT, we isolated islets and measured insulin 
secretion. Basal insulin secretion, glucose-stimulated insulin secretion (GSIS), cAMP-potentiated GSIS 
(pGSIS), and islet insulin content were similar to those of  control islets in both the β Δ11 and Panc Δ11 models 
(Figure 1, E–J, and Supplemental Figure 2, H–J). We also perifused islets from Panc Δ11 animals and found 
that GSIS and pGSIS were similar between control and Panc Δ11 islets (Supplemental Figure 1, M and N).
To address whether Ca2+ handling was impaired in murine β cells with loss of CFTR function, as pre-
viously reported (12), we assessed Ca2+ handling in single β cells isolated from β Δ11 animals. We found that 
glucose-stimulated Ca2+ handling in single β cells was similar to that of control β cells (Supplemental Figure 1, 
O–R). These results suggest that CFTR did not intrinsically regulate murine β cell insulin secretion or content.
Key islet regulatory gene expression was not affected by CFTR deletion. Given the β cell dysfunction and dis-
turbed ion flux reported by others in a CF murine model (12) and the ability of  β cell dysfunction to affect the 
islet transcriptome (37), we performed RNA sequencing on whole islets from both murine models. Evaluation 
of  selected islet-enriched transcripts revealed few differences in expression over 2-fold change between control 
and experimental animals of  either model (Supplemental Figure 1, S and T).
Human islet endocrine cells showed minimal CFTR mRNA expression that did not result in detectable CFTR 
protein. To determine whether CFTR has a role in insulin secretion in human β cells, we investigated 
CFTR expression and function in human islet endocrine cells. We first searched 3 previously published 
gene expression data sets of  FACS-sorted β and α cells based on intracellular or extracellular labeling 
methods and single-cell sequencing of  endocrine and exocrine cell types for CFTR and comparator tran-
scripts (38–40). RNA sequencing of  270 single β cells isolated from nondiabetic and diabetic individuals by 
Segerstolpe et al. (38) (Figure 2A and Supplemental Figure 3A) and of  sorted β cells by Blodgett et al. (39) 
(Figure 2B and Supplemental Figure 4A) and Bramswig et al. (40) (Supplemental Figure 4C) revealed that 
CFTR transcript was minimally expressed in β cells. Of  270 single cells in the Segerstolpe et al. (38) data 
set, approximately 5% of  β cells displayed CFTR reads per kilobase of  transcript per million mapped reads 
(RPKM) values >1, with a maximum CFTR expression value of  4.2 RPKM (Supplemental Figure 3E). For 
comparison, GLRA1, a chloride channel that we have previously shown to effect β cell stimulus-secretion 
coupling (41), was expressed at RPKM values >1 in approximately 40% of  β cells, with a maximum expres-
sion value of  123.2 RPKM. CFTR expression, when detected, was also several fold less than islet-enriched 
transcription factors important in β cell identity maintenance and insulin secretion (Figure 2, A and B).
Minimal CFTR expression in the aforementioned data set (38) was also found in other islet endocrine 
cells. Approximately 3% of  874 α cells expressed CFTR transcript at RPKM values >1, with a maximum 
expression of  5.6 RPKM (Supplemental Figure 3, B and F), and approximately 4% of  the 114 δ cells 
expressed CFTR with RPKM values >1, with a maximum expression of  14.9 RPKM (Supplemental Fig-
ure 3, C and G). Single exocrine cells, as we expected, expressed relatively high levels of  CFTR and other 
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Figure 2. CFTR mRNA expression was minimal in human β cells, and CFTR protein was undetectable in human β cells. Expression of CFTR and 
select β cell–related transcripts from published islet cell transcriptomes: (A) 270 single human β cells from 6 healthy and 4 diabetic donors (reads per 
kilobase of transcript per million mapped reads [RPKM], Segerstolpe and Palasantza et al., ref. 38) and (B) sorted β cells from 7 healthy adult donors 
(transcript per kilobase million [TPM], Blodgett et al., refs. 39). Note: Individual expression values are not presented in A, as the log2 of the mean 
expression value of 270 β cells was calculated to account for the approximately 85% of β cells in this data set that do not express CFTR; individual 
CFTR expression values are presented in Supplemental Figure 3E. Green bar, insulin; blue bars, key islet transcription factors; pink, islet hormone 
secretion related genes; red, CFTR. (C) Representative immunohistochemical labeling of CFTR (red), insulin (green), and glucagon (purple) in a 
pancreas from 3-month-old male donor. Insets depict the islet border and interior. (D) CFTR (red) channel alone (note: CFTR ductal localization and 
islet absence). Scale bars: 50 μm (C and D); 10 μm (insets). (E) Representative patch clamp recording of a human β cell and a INS832/13 + wtCFTR cell 
(n = 5 donors, 35 β cells; Supplemental Figure 5B). (F) Insulin secretion from human islets (n = 4 donors) in medium containing 1 mM glucose (1 G), 
16.7 mM glucose (16.7 G), or 16.7 G plus 100 μM forskolin (16.7 G + Fsk) and no drug (white), 1 μM VX770 (blue, ivacaftor), 5 μM VX661 (green), or 5 μM 
VX809 (red, lumacaftor). 1 G, n = 22–24 replicates; 16.7 G, n = 11–12 replicates; 16.7 + Fsk, n = 10–12 replicates. VX770 is a selective CFTR potentiator 
that increases CFTR activity at the membrane and VX661, and VX809 are CFTR channel correctors that increase membrane channel density. Data rep-
resent mean ± SEM. No statistical significance (P < 0.05) was observed in in vitro human islet insulin secretion when comparing secretory responses 
at 1 G, 16.7 G, and 16.7 G + Fsk in the presence of absence of CFTR modulators. One-way ANOVA was used for statistical analysis.
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markers of  exocrine tissue (Supplemental Figure 3, D and H). Thus, 3 independent human islet cell gene 
expression data sets found minimal expression of  the CFTR transcript.
We also investigated CFTR protein expression and location in the human pancreas. Since suitable anti-
bodies for detection of  CFTR protein have been problematic (42), we sought to identify a specific antibody 
for detection of  CFTR protein by screening the specificity of  3 anti-CFTR monoclonal antibodies (antibodies 
217, 432, 450) from the Cystic Fibrosis Foundation (CFF) against HeLa cells (which did not express CFTR), 
HeLa CFTR cells (which expressed human CFTR), and the Calu-3 line (which endogenously expressed 
CFTR). Using immunocytochemistry, we found that antibody 217 nonspecifically labeled all cells and anti-
bodies 432 and 450 specifically labeled CFTR protein. However, we observed some nonspecific labeling of  
antibody 450 on HeLa cells and determined that antibody 432 was most suited for detecting human CFTR 
protein (Supplemental Figure 5A). Using this validated antibody, we labeled human pancreatic sections 
from 4 normal human donors over a range of  ages (1 day to 4 years) and found that CFTR protein was 
localized to the ducts of  the pancreas but was not present in insulin-positive, glucagon-positive (Figure 2, C 
and D, and Supplemental Figure 3, C–H), or somatostatin-positive (Supplemental Figure 5, I–P) cells. This 
staining pattern was also observed in human pancreata studied by The Human Protein Atlas (43). These 
data indicate that CFTR protein was not detectable in human islet endocrine cells by immunochemistry.
To determine if  functional CFTR protein was present in human β cells, we recorded forskolin-activated 
and chloride currents sensitive to the channel inhibitor CFTR(inh)-172 in human β cells but did not detect 
CFTR(inh)-172–sensitive chloride currents (Figure 2E and Supplemental Figure 5B). To further assess 
whether functional CFTR protein was present in human β cells, we incubated human islets with 3 specific 
modulators of  CFTR function, VX770 (ivacaftor), a CFTR potentiator, and VX661 (tezacaftor) and VX809 
(lumacaftor), both CFTR correctors, and measured insulin secretion in response to nonstimulatory and 
stimulatory conditions. Insulin secretion in the presence of  each CFTR modulator was similar to untreated 
islets at 1 mM glucose, 16.7 mM glucose, and 16.7 mM glucose + 100 μM forskolin (Figure 2F). Taken 
together, these data indicate that CFTR did not intrinsically control human β cell membrane potential or 
insulin secretion.
Analyses of  human CF pancreata and islets. To examine the effect of  CF-causing mutations on insulin 
secretion, we established a nationwide network to obtain and study pancreas, islets and deidentified 
medical records from CF donors and healthy age-matched donors. To maximize the data collected 
from CF pancreata, we developed a protocol to obtain pancreatic tissue and isolate islets from a single 
CF organ. This approach allowed for integrated investigation of  pancreatic tissue, CFTR mutations, 
islet function, islet gene expression, and immune activity (Figure 3). We obtained 7 CF pancreata from 
2013–2017 from individuals with the diagnosis of  CF (Table 1). All donors had pancreatic insufficien-
cy, with numerous clinical contacts, medical procedures, and medications. All the donors but donor 
1 were diagnosed with CFRD (Table 1). C-peptide measured in blood taken at the time of  organ pro-
curement in 3 CF donors was in the normal to elevated range (1.83–4.54 ng/ml), while one donor had 
low C-peptide (0.04 ng/ml) (Table 1).
CF distorted the pancreatic islet niche and reduced β cell area. To examine the islet niche in the setting of  
CF, we interrogated CF pancreatic tissue by measuring β cell area, endocrine cell populations, amyloid 
deposition, β cell proliferation, and apoptosis. The gross anatomic appearance of  each CF pancreas was 
abnormal. CF pancreata were fatty and fibrotic in appearance (Supplemental Figure 6). CF pancreata were 
almost completely devoid of  exocrine tissue and displayed large aggregations of  islets, regions of  pancre-
atic lipomatosis and fibrosis, cyst-like structures, and dilated duct-like structures (Figure 4, A–C), as also 
described by others (10, 17, 18, 44). Abnormal islet aggregation (Figure 4E), disruption of  islet structure, 
endocrine cell scattering, and intraislet dilated duct-like structures (Figure 4F) were also observed. How-
ever, some islets appeared morphologically “normal,” but all islets were present in ectopic niches, i.e., 
encased in adipose and/or fibrotic tissue.
Pancreatic β cell area in CF donors was reduced approximately 65% (Figure 4D), with the majority of  
CF β cell area confined to large islet aggregations. We also found an increased contribution of  α cells, but 
not β or δ cells, to the endocrine compartment (α, β, δ cells) of  the CF pancreas (Figure 4G). We did not 
find differences in β cell apoptosis or proliferation (Supplemental Figure 7, A and B) with the exception of  
increased β cell apoptosis in donor 6 (Figure 4H). We also found intraislet amyloid in donors 1 and 5 (pre-
vious report, ref. 10) (Figure 4I). These data demonstrate that the islet niche, islet morphology, and pan-
creatic β cell area were altered in CF, which likely affects in vivo hormone secretory and delivery capacity.
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Stimulated insulin and glucagon secretion and key islet regulatory genes were maintained in CF islets. To deter-
mine the secretory profile CF islets, we simultaneously measured in vitro CF islet insulin and glucagon 
secretion by perifusion. Following normalization of  islet secretion to islet equivalents (IEQs), total hor-
mone content, and conditions of  maximal stimulation, 5 of  5 CF donors displayed phasic GSIS, pGSIS, 
hypoglycemic epinephrine inhibition of  insulin secretion, and KCl-mediated insulin secretion (Supple-
mental Figure 8, A–E). CF islet insulin secretory profiles (normalized to IEQ and insulin content) dis-
played insulin secretory responses above, within, or below the range of  normal islets (Figure 5, A and 
C, and Supplemental Figure 9). There was a statistical difference between CF and normal islet insulin 
secretory values (normalized to IEQ or percentage content) when all values (n = 5 donors/group × 50 
values/perifusion = 250 insulin secretory values) were compared (IEQ: P = 0.0021; percentage content: 
P < 0.0001). To further investigate possible differences in CF and normal islets, we performed additional 
statistical analyses and found that insulin secretion was not equal between CF and normal islets at all 
time points (P < 0.0001); there was only one significantly different time point in the IEQ normalization 
(t = 126 minutes, during perifusion with 5.6 G + KCl) and there were no significantly different time 
points in the percentage content normalization, using Sidak’s multiple comparison test. However, when 
aggregating insulin secretory values across all time points, there were no significant differences between 
CF and normal insulin secretory responses (IEQ: P = 0.8231; percentage content: P > 0.999). Important-
ly, these analyses indicate that the mean CF insulin secretory response to a number of  conditions was 
similar to that of  normal islets, regardless of  normalization (Figure 5, B and D, and Supplemental Figure 
9). To further investigate islet insulin secretion, we calculated the insulin secretion AUC and found no 
significant differences in insulin secretion AUC between CF and normal donors (Supplemental Figure 
10). Additionally, the CF islet insulin content and stimulation index were similar to those of  normal 
islets (Figure 5, E and F). CF islet glucagon secretion was similar to that of  control islets; however, we 
observed elevated glucagon secretion in some donors when secretion was normalized to glucagon con-
tent and 1.7 mM glucose plus 1 μm epinephrine (Supplemental Figures 11 and 12). Taken together, these 
data suggest that CF β cell insulin secretion, in particular GSIS and pGSIS, and glucagon secretion were 
similar to those of  control islets.
To examine gene expression in CF islets, we performed whole-islet RNA sequencing on islets from 5 
CF donors and examined transcripts important in islet cell identity, maintenance, and hormone secretion. 
CF islets had few gene expression changes over 2-fold, compared with healthy islets, in selected islet-en-
riched transcripts, with the exception of  ARX (Figure 5G).
CF pancreata and islets were infiltrated by immune cells. Given the extent of  remodeling of  the CF pancreas, 
we hypothesized that the CF pancreas and islets would be infiltrated by immune cells, a process reported to 
contribute to both T1D (45, 46) and T2D (47, 48). To investigate this hypothesis, we stained pancreatic sec-
tions for the pan-immune cell marker CD45 and found a profound immune infiltration of  the CF pancreas 
and islets (Figure 6, A and B). The infiltrate was both peri-islet and intraislet (Figure 6, A and B, insets). 
CD45+ cells were also observed throughout the remnant CF pancreas (Figure 6, A and B). Approximately 
5% of  the CF pancreas was composed of  CD45+ cells, an approximately 5-fold increase compared with 
normal pancreas (Figure 6C). RNA sequencing of  whole CF islets also revealed an approximately 5-fold 
Figure 3. Pancreatic processing allowed for multidisciplinary investigation of the CF pancreas. Acquisition of intact pancreatic tissue and islets from the 
same pancreas allowed for integration of in situ pancreatic characteristics with in vitro islet function, the islet transcriptome, and islet immune infiltration.
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increase in PTPRC (also known as CD45) transcript expression (Figure 6E). We also determined the num-
ber of  CD45+ cells within 20 μm of  islets in CF donors (Figure 6D) and discovered that the majority of  
CF donors met the numerical criterion (3 islets with 15 CD45+ cells in proximity of  the islet) for insulitic 
classification; however, CF islets did not display overt (pseudo)atrophic islets (also required for this insulitis 
classification) that are a hallmark of  T1D (49).
To further characterize the nature of  immune islet infiltration, we performed DAVID and Ingenuity 
pathway analysis analyses of  the CF islet transcriptome. Pathway analyses demonstrated significant acti-
vation of  numerous immune pathways related to immune cell homing, activation, and signaling (Supple-
mental Figure 13, A and B). In addition, transcripts related to innate and adaptive immune cells, immune 
chemotactic and signaling chemokines, inflammatory cytokines, and generalized immune signaling and 
homing were increased in CF islets (Figure 6E). These data demonstrate immune cell infiltration of  the 
CF islet as well as a complex immune signaling environment within the CF islet.
To characterize the adaptive CF islet immune infiltrate, we sorted T cells from islets of  one islet 
preparation (donor 5), using a method previously described for the islets of  donors with T1D (50). We 
found 4 types of  islet-infiltrating T cells: CD3+CD8+ naive T cells, stem cell memory T cells, CD45RA– 
central memory and effector T cells (Supplemental Figure 14, A–H). The phenotypes and presence of  
these T cells likely indicate an ongoing islet-infiltrating immune response. Forty-two T cell lines were 
also cultured from islets of  donor 5. These consisted of  CD4 lines (n = 10), CD8 lines (n = 9), and lines 
containing both CD4 and CD8 T cells (mixed) (n = 23), all of  which were phenotyped. A represen-
tative CD8+ T cell line that displayed moderate IFN-γ and high TNF-α production upon stimulation 
is shown in Figure 6, F–H. CD4 lines generally expressed low levels of  proinflammatory cytokines 
(IFN-γ and TNF-α) and undetectable to low levels of  a degranulation marker (CD107a) (Supplemental 
Table 1). The CD8 lines strongly expressed proinflammatory cytokines and the degranulation marker 
(Supplemental Table 2). CD4 T cells within the mixed lines were moderately proinflammatory upon 
stimulation, while CD8 T cells within the mixed lines were strongly proinflammatory (Supplemental 
Table 3). These data suggest that an adaptive immune infiltration of  CF islet was capable of  producing 
inflammatory cytokines, which impair in vivo β cell function (51).
Table 1. Demographic and CF-causing variants in CF donors
No. Age (yr) Sex BMI CFTR variant 1 CFTR variant 2 Variant class Diabetes C-peptide (ng/ml)
1A,B (black) 25 M 19.1 c.1521_1523delCTT 
(p.Phe508del) (legacy: 
Δ F508)
c.1521_1523delCTT 
(p.Phe508del)  
(legacy: Δ F508)
II,II No 2.26
2A,B (blue) 22 F 21.8 c.1521_1523delCTT 
(p.Phe508del)  
(legacy: Δ F508)
c.2846G > A 
(p.Trp1282X)  
(legacy: W1282X)
II,I Yes, duration 
unknown
4.54
3A,B (green) 34 F 14.7 c.1521_1523delCTT 
(p.Phe508del)  
(legacy: Δ F508)
c.1521_1523delCTT 
(p.Phe508del) (legacy: 
Δ F508)
II,II Yes, 6–10 yr 1.83
4A,B (red) 24 M 24.1 c.1521_1523delCTT 
(p.Phe508del)  
(legacy: Δ F508)
c.1521_1523delCTT 
(p.Phe508del) (legacy: 
Δ F508)
II,II Yes, >10 yrs 0.04
5A (teal) 34 F 17.0 c.1521_1523delCTT 
(p.Phe508del)  
(legacy: Δ F508)
c.1521_1523delCTT 
(p.Phe508del) (legacy: 
Δ F508)
II,II Yes, 6–10 yr ND
6 (pink) 20 M 16.9 c.1521_1523delCTT 
(p.Phe508del)  
(legacy: Δ F508)
c.1521_1523delCTT 
(p.Phe508del) (legacy: 
Δ F508)
II,II Yes, ~7 yr ND
7A,B (purple) 42 F 27.7 c.3909C > G 
(p.Asn1303Lys) 
(legacy:N1303K)
c.1657C > T 
(p.Arg553X) 
(legacy:R553X)
II,I Yes, <1 yr ND
AIslet isolation; Bwhole-islet RNA sequencing. All donors were of European descent. Donor color designations correlate with data presented in Figure 4, 
D and G; Figure 5, A, C, and E; and Figure 6, C and D. ND, not determined. There are 5 CFTR mutation classes that cause CF. Classes I–III cause the most 
severe forms of CF. All donors had class I mutations, which result in no production of CFTR protein, and/or class II mutations, which disrupt protein folding 
and membrane localization. Legacy name refers to the mutation in the Cystic Fibrosis Mutation Data base (http://www.genet.sickkids.on.ca/app).
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Discussion
The increasing prevalence of  CFRD, its effect on CF patients, and the recent suggestion that CFTR reg-
ulates islet hormone secretion have made the etiology of  CFRD a subject of  intense scrutiny. Studies of  
CFTR in islet cell lines (12, 14, 16), ferret/rodent islets (11–13, 15, 16, 20, 25, 35), human islets (11, 15), 
and CF patients (18, 21, 22, 24, 26–28, 52) have suggested that intrinsic dysregulation of  α and β cell 
secretion and/or islet loss caused by pancreatic destruction contribute(s) to CFRD pathogenesis. Impor-
tantly, islet-intrinsic CFTR regulation of  insulin and glucagon secretion by α and β cells would identify new 
mechanisms regulating islet hormone secretion and represent a targetable pathway for CFRD treatment. 
Figure 4. CF pancreata were severely remodeled, with ectopic adipose and fibrotic tissue deposition accompanied by β cell loss. Characteristic CF-relat-
ed pancreatic pathology observed in (A) donor 1: islet aggregations (black arrowhead) with inter-islet fibrosis (blue arrowhead) and islets in adipose niches 
(yellow arrowhead). Pathology observed in (B) donor 2: ectopic adipose (white arrowhead) and fibrotic deposition (red arrowhead). (C) Pathology observed 
in donor 3: formation of fibrotic cyst-like structures with embedded dilated duct-like structures (red arrowhead) and islets in fibrotic niches (black arrow-
head). The pancreata from all donors lacked discernible exocrine tissue. Scale bars: 500 μm. (D) β Cell area of CF donors (n = 7) compared with healthy 
pancreatic donors (n = 7). Examples of abnormal islet morphology: (E, donor 1) islet aggregations and (F, donor 2) scattering of islet cells and dilated 
structures within and around islets. Scale bars: 100 μm. (G) Percentage of β, α, and δ cells relative to all β, α, and δ cells in the CF pancreas (n = 7) compared 
with healthy donors (n = 5). Additional islet abnormalities observed in a subset of CF pancreata in (H) donor 6: β cell apoptosis (scale bar: 100 μm; 20 μm 
[insets]) quantified in Supplemental Figure 7 and (I) intraislet amyloid, as detected by Thioflavin S in 2 of 7 donors (scale bar: 100 μm; 15 μm [insets]). 
Data represent mean ± SEM. Statistical significance (P < 0.05) was observed in β cell area and α cell ratio where noted by the asterisk. Unpaired 2-tailed 
Student’s t test was used for statistical analysis. The squares and dots represent individual donors and are color coded according to CF donor (Table 1).
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Because there is limited and contradictory information regarding CFTR expression and function in islets, 
we used two murine models of  β cell CFTR deletion as well as healthy and CF pancreata and islets to study 
expression of  CFTR in human islets, whether CFTR controls islet hormone secretion, and CF pancreas 
and islet pathology. Specific deletion of  CFTR from β cells in two murine models did not alter glucose tol-
erance or in vitro β cell function, indicating CFTR is not involved in murine β cell stimulus-secretion cou-
pling. Studies of  normal human pancreata and islets found that expression of  CFTR mRNA was minimal 
and that CFTR protein and function were not detectable in islet endocrine cells. We also report for the first 
time to our knowledge that in vitro insulin and glucagon secretion by human CF/CFRD islets was similar 
to normal human islets and the CF/CFRD islet-regulatory transcriptome was essentially intact. In addi-
tion, we observed profound pancreatic pathology in human CF donors (observed by others, refs. 17, 18, 
44, 53, 54) with loss of  β cell area, islet dysmorphia, and now reported details of  islet-infiltrating immune 
cells. These studies demonstrate that CFTR does not directly regulate insulin or glucagon secretion and 
that CFRD is primarily caused by pancreatic damage, intraislet inflammation, in vivo islet dysfunction, and 
islet loss in the setting of  a progressive multiorgan disease (Figure 7).
In CF murine models, complete loss of  β cell function with impaired animal glucose tolerance (12) and 
preserved β cell function with age-related β cell loss and worsening glucose tolerance (25) have both been 
reported. In the CF ferret model, which recapitulates the pancreatic exocrine pathology of  human CF (CF 
mice do not, ref. 54), impaired glucose and mixed meal intolerance and impaired islet function have been 
consistently shown (13, 20, 35). However, reduced β cell mass (13, 20, 25), fluctuating insulin resistance 
(25), pancreatic inflammation (20), and an unidentified exocrine-derived paracrine factor (35) have been 
reported and linked to nutrient intolerance and β cell dysfunction in these models. In the single report that 
concluded that β cell CFTR loss in CF mice caused β cell dysfunction and impaired glucose tolerance, β cell 
mass and insulin sensitivity were not examined (12). Our murine models of  β cell–specific CFTR deletion 
allowed us to determine whether the CFTR contributes directly to β cell function without metabolic and 
pancreatic abnormalities caused by whole-animal CFTR loss. Integrating our data with other reports (20, 
25, 35) indicates that nutrient intolerance and β cell dysfunction in CF models were not caused directly by 
β cell CFTR loss but by other effects (i.e., insulin resistance, β cell loss, pancreas/islet inflammation) caused 
by whole-animal CFTR deletion.
In vitro experiments using CFTR inhibitors have also been used to ascribe a role for CFTR in the intrin-
sic control of  β cell secretory function. In murine islets, one study reported complete loss of  in vitro GSIS 
(12), while another reported maintenance of  in vitro GSIS with a reduction in pGSIS (11). In ferret islets, 
CFTR(inh)-172 caused β cell dysfunction in both wild-type and CFTR-knockout ferret islets, indicating 
nonspecific effects of  this CFTR inhibitor (35). One study of  β cell CFTR function has used human islets, 
was dependent on the use of  CFTR inhibitors, and found only impaired pGSIS with no effect on basal or 
GSIS (11). Recent evidence has shown that CFTR inhibitors cause inhibition of  CFTR-independent chlo-
ride currents (55), cellular toxicity (55), increased production of  reactive oxygen species, and reduction of  
mitochondrial membrane potential (56). This suggests that the use of  CFTR inhibitors has limitations in 
determining if  CFTR intrinsically controls β cell function. By taking care to limit the exposure of  human 
islets to the inhibitor, with no preincubation period, we did not detect CFTR-mediated chloride currents in 
human β cells. In vitro human islet insulin secretion in the presence of  specific CFTR modulators (VX770, 
VX661, VX809) was not changed. These studies differ from the conclusion of  a small pilot study in humans, 
suggesting that ivacaftor (VX770) directly improves in vivo β cell secretory function in individuals with CF 
(52). An alternative explanation is that ivacaftor ameliorates CF pathophysiology in other tissues, leading 
to clinical improvement and indirectly improving insulin secretion and glucose tolerance. Taken together, 
these data suggest that CFTR does not intrinsically regulate human β cell insulin secretion.
The CFTR transcript was minimally expressed (and in most cells undetectable) and CFTR protein was 
not detected in islet endocrine cells. These results contrast with those of  previous studies reporting CFTR 
Figure 5. CF islet insulin content, glucose-stimulated insulin secretion, and islet gene expression were similar to healthy control islets. Individual donor 
(A) and mean (B) insulin secretion perifusion traces of CF islets (n = 5) compared with normal islets (shaded area, dotted black lines, n = 5) normalized to islet 
equivalents (IEQ). Individual donor (C) and mean (D) insulin secretion perifusion traces of CF islets (n = 5) compared with normal islets (shaded area, n = 5) 
normalized to insulin content. Entire perifusion traces are in Supplemental Figure 8. Stimulation index (E) comparing the ratio of 16.7 G/5.6 G insulin secretory 
rates. (F) Islet insulin content and (G) whole-islet fold changes of key islet regulatory transcripts in CF islets (n = 5) relative to whole healthy islets (n = 5). Data 
represent mean ± SEM. No statistical difference (P < 0.05) was detected using an unpaired 2-tailed Student’s t test in E and F. Ordinary 2-way ANOVA was 
used to compare islet perifusions and is discussed in the text. The dots represent individual donors and are color coded according to CF donor (Table 1).
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Figure 6. CF pancreas and islets showed marked immune infiltration. CD45 (red) and insulin (green) labeling of CF pancreata from (A) donor 1 and 
(B) donor 2. Magnification of boxed areas shows populations of CD45+ cells at the periphery and within islets (scale bars: 100 μm; 50 μm [insets]). (C) 
Percentage contribution of CD45+ cells to CF and normal pancreata. (D) Number of CD45+ cells identified within 20 μm of islets (n = 25 islets/donor) from 
CF donors (n = 6). The dots represent individual islets and are color-coded according to CF donor (Table 1). Each concentric circle represents the number 
of immune cells within 20 μm of the islet, and each arrow indicates the number of immune cells in that concentric circle. The number increases outward. 
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localization to cultured single human β and α cells using a relatively concentrated primary antibody (11, 
15). Furthermore, the reported labeling of  human pancreatic tissue (15) was not accompanied by clear α 
and β cell staining, which would be expected given the reported single cell labeling (11, 15) and, impor-
tantly, did not show the distinct ductal localization of  CFTR. Furthermore, our experiments demonstrating 
the lack of  human islet CFTR expression are supported by electrophysiologic and in vitro insulin secretion 
experiments, the Human Protein Atlas (43), 3 islet endocrine cell transcriptomes (38–40), and single-mole-
cule fluorescent in situ hybridization (35).
We noted various disruptions in islet morphology, including aggregation of  islets, islet cell scattering, 
and islets with intervening duct-like structures, likely caused by destruction and collapse of  the exocrine 
tissue, and subsequent adipose and fibrotic tissue deposition. Whatever the cause of  reduced islet mass and 
islet dysmorphia, pancreatogenic diabetes has been reported to occur when approximately 65% of  β cell 
area is lost (57), suggesting that the loss of  β cells observed in our study may be sufficient to cause CFRD.
By obtaining islets from the same pancreata, we also evaluated in vitro hormone secretion and the tran-
scriptome of human CF islets. In contrast to previous reports of impaired β cell function in CF models (11–13, 
35), we found that human CF islets had appropriate basal insulin secretion and dynamic GSIS, and pGSIS, 
with insulin secretory profiles and islet insulin content similar to that of 5 age-matched healthy donor islets 
(Figure 5). In addition, isolated CF islets secreted glucagon in a manner similar to normal islets, with similar 
islet glucagon content. Importantly, we studied islets with severe CF-causing class I and/or class II CFTR 
mutations, which are predicted to result in no CFTR or improper protein processing/trafficking (Table 1). CF 
islets also maintained expression of many key islet-regulatory transcripts, indicating that islet cell identity was 
preserved. Taken together, these results not only indicate that CFTR does not intrinsically regulate human islet 
hormone secretion, but that the remnant CF islets are functional in vitro, which may be clinically significant.
We present for the first time to our knowledge a detailed characterization of  an increased inflamma-
tory potential within the human CF islet that is evidenced by increased expression of  several cytokines/
chemokines (including IL6, IL1B, CXCL10, TNFA, and IFNG) and high levels of  TNF-α and IFN-γ produc-
tion by stimulated T cells isolated from CF islets. We postulate that islet isolation from the CF pancreas 
removes the islet from the inflammatory environment, limiting the effect of  cytokines/chemokines, allow-
ing for relatively normal in vitro islet secretion of  insulin and glucagon. Thus, we propose that intraislet 
and islet-proximal immune cells are stimulated in vivo by exocrine tissue destruction and remodeling to 
produce and secrete chemokines/cytokines, which are known to impair islet secretory function (58).
There are caveats to the current studies. First, our murine models used a conditional exon 11–null 
allele (36). This null allele may not generate a mutant protein, leading to a hypothesized role of  ER stress 
caused by CF-causing mutations (59). The ΔF508 mutation alone in mice does not recapitulate the severe 
CF phenotype observed in humans (60), and, thus, we choose to use an null allele that completely ablates 
CFTR function, analogous to the CF ferret model (36, 61). Furthermore, we have shown that RNA was 
transcribed without exon 11 in our model (36), which increased our chances of  creating β cell dysfunction 
caused by ER stress. Second, our OGTT studies were performed on animals that were conscious, which 
has the potential to stress animals. Third, we presume pancreatic autolysis also caused the approximately 
65% reduction in β cell area. However, we cannot rule out that β cell development was affected by CFTR 
dysfunction, as inhibition of  CFTR has been shown to augment endocrine cell development (62) and, 
recently, β deficiency and impaired growth capacity of  β cells in infants and young children with CF have 
been reported (63). Our studies also used CF pancreata and islets from chronically ill individuals taking 
many medications prior to death. How this influences islet function is not known, but the relatively pre-
served islet hormone secretion and islet gene expression does not suggest a major impact. We observed a 
quantitatively variable islet hormone secretion profile from CF islets, which may reflect differing clinical 
conditions, levels/persistence of  inflammation, and/or islet isolation challenges presented by these patho-
logic pancreata. Investigating the cause of  CFRD in humans is complicated by life-long illness and exten-
sive and complex medical histories; however, no alternative approach appears feasible.
(E) Selected immune-related genes from whole-islet RNA sequencing of CF donors (n = 5) versus healthy donors (n = 5). T cell lines grown from donor 5 
islets were stimulated with and without soluble anti-CD3 overnight and soluble anti-CD28, GolgiPlug, and CD107a staining antibody were then added to all 
wells for 6 hours. Intracellular staining of a representative CD8+ T cell line is shown for (F) CD107a, (G) IFN-γ, and (H) TNF-α. Data represent mean ± SEM. 
Statistical significance (P < 0.05) was observed in the percentage of pancreatic CD45+ cells indicated by the asterisk. Unpaired 2-tailed Student’s t test was 
used for statistical analysis.
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We postulate that the aforementioned factors combined with metabolic and nutrient-signaling derange-
ments caused by malnutrition/malabsorption (21, 23, 64, 65), gastrointestinal impairments, multiorgan 
failure, chronic illness, chronic infection (66), and intermittent insulin resistance overlaid on genetic diabet-
ic susceptibility (9) combine to cause insufficient in vivo insulin secretion and CFRD (Figure 7).
Importantly, our studies indicate that remaining islets in CF/CFRD are functional, highlighting 
the importance of  efforts to limit pancreatic destruction and inflammation. Additionally, treatment 
with agents that improve β cell function and/or islet health, such as GLP1R agonists, might be consid-
ered for prevention and treatment of  CFRD. Our studies also suggest that new modulators of  CFTR 
function do not directly affect β cell function, but their ability to improve overall health or limit pan-
creatic exocrine inflammation and pathology may lead to improved diabetes management. Further-
more, continued investigation of  CFRD may provide important insights into islet resiliency, pancreatic 
Figure 7. Integrated model of CFRD pathogenesis. Pancreatic autolysis and remodeling results in destruction of the islet niche and environment, β cell 
loss, and immune infiltration. Islet loss and inflammation combined with the numerous physiological derangements observed in CF, particularly those 
responsible for nutrient assimilation, lead to insulin insufficiency and CFRD.
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exocrine-endocrine interaction, and islet-nutrient signaling axes, which may be applicable to the treat-
ment of  all forms of  diabetes.
Methods
Generation of  β cell Cftr deletion models. A model of  inducible and β cell–specific excision of  exon 11 
(β Δ11) was generated by crossing female mice heterozygous for a conditional (Cftr tm1Cwr, also known 
as Cftr FL11) and null Cftr exon 11 (Cftr Δ11) (from M. Drumm, Case Western Reserve University) (36) 
with heterozygous Cftr FL11/ Cftr Δ11 male mice carrying a B6.Cg-Tg(Ins1-cre/ERT)1Lphi/J (MIPCreERT) 
transgene (from L. Phillipson, University of  Chicago, Chicago, Illinois, USA) (67), both on a C57/BL6 
background. Importantly, Cftr exon 10 is “legacy nomenclature” for Cftr exon 11 and was used in the 
initial description of  the animal (36). Cftr FL11/Cftr Δ11 MIPCreERT animals were given 3 subcutaneous 
injections of  6 mg tamoxifen (MilliporeSigma) over 5 days to induce exon 11 recombination or inject-
ed with vehicle (V) and allowed to recover for at least 2 weeks (68). To achieve maximal Cftr exon 11 
recombination, we focused on heterozygous Cftr FL11/Cftr Δ11 MIPCreERT animals. Homozygous Cftr FL11 
MIPCreERT (β Δ11*) and control mice (V) were also investigated (Supplemental Figure 2). Mice with 
pancreatic/constitutive deletion of  Cftr exon 11 (Panc Δ11) were generated by crossing Cftr FL11 and wild-
type exon 11 allele (Cftr wt) heterozygous female mice to heterozygous Cftr FL11/ Cftr wt males carrying the 
B6.FVB-Tg(PDX1-cre)6Tuv/J (PDXCretuv) transgene (purchased from the Jackson Laboratory) (69). 
Both models and analyses are summarized in Figure 1, A and B. In the β cell–specific/inducible mod-
el, pretreatment (Pre-Tx) animals were 8–14 weeks old and V and β 
Δ11 animals were 12–19 weeks old. 
Panc Δ11 and Panc wt animals were 9–25 weeks of  age. By RNA sequencing, β Δ11 animals showed near 
100% reduction in whole-islet Cftr exon 11 expression (Supplemental Figure 1A). In Panc Δ11 animals, 
we found no Cftr exon 11 expression, which was also absent in Panc wt islets (Supplemental Figure 1G). 
OGTT and islet studies were performed on both male and female mice.
OGTT. OGTT was performed after a 6-hour fast on conscious animals. Plasma glucose was measured 
from whole blood, taken from the tail, with an Accu-chek glucose meter (Roche Diagnostics) prior to and 
15, 30, 60, 90, 120, and 150 minutes after oral gavage of  a 2 g/kg glucose bolus.
Mouse islet isolation and measurement of  islet insulin secretion and Ca2+. Mouse islets, isolated as previously 
described (70), were hand picked under microscope guidance and cultured overnight in DMEM (Milli-
poreSigma) supplemented with 5.6 mM glucose, 10% FBS (Millipore) and 1% Penicillin/Streptomycin 
(Gibco) at 37°C. Islets from experimental and control animals were size matched into 3 replicates and 
placed on Millicell Cell Culture Inserts (Millipore) in nontissue-treated 24-well plates. Islets were equil-
ibrated in DMEM supplemented with 5.6 mM glucose for 45 minutes at 37°C and then incubated for 1 
hour at 37°C in 5.6 mM glucose, 16.7 mM glucose, and 16.7 mM glucose plus 100 μM 3-isobutyl-1-meth-
ylxanthine (MilliporeSigma). The slightly higher basal glucose concentration (5.6 mM) compared with 
some other studies (e.g., 1 mM or 2.8 mM) was used to ensure uniformity between mouse and human 
studies. This is the reason the reported fold changes were observed. After each incubation, media were 
collected, and upon assay completion, islets were incubated in acid ethanol for at least 48 hours at 4°C and 
the supernatant was collected. All samples were stored at –80°C until insulin measurement by radioimmu-
noassay from Millipore (catalog no. RI-13K) (32, 71).
For measurement of  intracellular Ca2+, islets were isolated from β Δ11 and control animals, dispersed 
into single cells with trituration in 0.005% trypsin (Gibco), cultured overnight at 37°C in RPMI 1640 (Gib-
co) supplemented with 11 mM glucose, 10% FBS, and 1% Penicillin/Streptomycin. Dispersed single cells 
were incubated for 20 minutes at 37°C in RPMI containing 2 μM Fura-2AM (Molecular Probes), followed 
by incubation with Krebs-Ringer bicarbonate buffer with 2 mM glucose for 20 minutes. Ca2+ imaging was 
performed as previously described (72).
Islet isolation from human CF pancreata. Pancreata from clinically diagnosed CF donors were identified 
via the International Institute for the Advancement of  Medicine (IIAM) or National Disease Interhange 
(NDRI) and shipped to the Institute of  Cellular Therapeutics at the Allegheny Health Network (Pitts-
burgh, Pennsylvania, USA) or the University of  Louisville for islet isolation (Table 1). Islet isolation 
was carried out according to a modification of  the method described by Ricordi et al. (73, 74). Digestive 
exogenous enzyme was injected into the duct and a stationary digestion was followed by mechanical 
and enzymatic digestion prior to tissue disruption and collection. Islets were resuspended in Connaught 
Medical Research Laboratories 1066 medium (Mediatech) supplemented with 10% heat-inactivated FCS, 
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100 units/ml Penicillin, 0.1 mg/ml Streptomycin, and 2 mmol/L L-glutamine (Life Technologies) (75); 
cultured overnight at the isolation center; and shipped overnight to Vanderbilt.
Control human islets were obtained through the Alberta Diabetes Institute IsletCore Program and 
the Integrated Islet Distribution Program and also isolated from normal pancreata obtained from the 
IIAM or NDRI by our team at the Allegheny Health Network. Human islet patch clamp experiments 
and static insulin secretion experiments were performed at the University of  Alberta, and islet perifusions 
were performed at Vanderbilt. A detailed summary of  human pancreas and islet donors is presented in 
Supplemental Spreadsheet 1.
Patch-clamp electrophysiology. For recording of  β cell currents, fire-polished patch pipettes (Sutter Instru-
ments) with a tip resistance of  4–7 MΩ were used for patch clamp recordings in the perforated-patch con-
figuration, using a EPC10 amplifier and Patchmaster software (HEKA Electronik). The bath solution was 
composed of  140 mM NaCl, 3.6 mM KCl, 0.5 mM MgSO4, 1.5 mM CaCl2, 10 mM HEPES, 0.5 mM 
NaH2PO4, 5 mM NaHCO3, and 1 mM glucose (pH adjusted to 7.4 with NaOH). The pipette solution 
contained 76 mM K2SO4, 10 mM KCl, 10 mM NaCl, 1 mM MgCl2, 5 mM HEPES, and 0.24 mM mg/
ml amphotericin B (pH adjusted to 7.3 with KOH). Cells were continuously perifused with bath solution 
at approximately 1 ml/min and 32°C. Rapid application of  10 μM forskolin, 10 μM forskolin plus 20 μM 
CFTR(inh)-172 (from the CFF), or control (bath solution only) was performed using a Fast-Step system 
(Warner Instruments). For positive control detection of  CFTR chloride currents, INS 832/13 cells (from 
C. Newgard at Duke University, Durham, North Carolina, USA) were transfected with plasmid vectors 
expressing either human CFTR and GFP or GFP alone using Lipofectamine 2000. In human islet experi-
ments, β cells were identified by immunostaining for insulin after patch clamping.
Human islet insulin secretion measurements. Human islets were perifused within 24 hours of  arrival 
at Vanderbilt, as previously described (32, 71, 76), with DMEM supplemented with the following glu-
cose concentrations and test agents: 5.6 mM glucose, 16.7 mM glucose, 16.7 mM glucose plus 100 μm 
IBMX, 1.7 mM glucose plus 1 μm epinephrine (MilliporeSigma), and 5.6 mM glucose plus 20 mM KCl 
(MilliporeSigma). Human insulin and glucagon secretion and content was measured in fractions and 
extracts by radioimmunoassay from MilliporeSigma (catalog no. RI-13K and GL-32K) (32, 71). Data 
were normalized to IEQ, total content, maximum KCl response, maximum IBMX response, and in the 
case of  glucagon, 1.7 mM glucose + 1 μm epinephrine. A glucose stimulation index (ratio of  16.7 mM 
glucose to 5.6 mM glucose secretion rates) was also calculated for perifusions. Human islet static insulin 
secretion measurements were performed at the University of  Alberta as previously described (77). The 
VX compounds were obtained from the CFF.
CFTR mutation identification. Genomic DNA was purified from flash frozen pancreatic tissue using the 
Wizard Genomic DNA Purification Kit (Promega). DNA analysis to identify CF-causing CFTR variants 
was performed by the Genetics Translational Technology Core at Johns Hopkins University. DNA samples 
were genotyped using a custom CFTR MassARRAY assay designed to screen for 159 disease-associated 
CFTR variants (78) and according to Johns Hopkins DNA Diagnostic Lab standard clinical operating pro-
cedures (Agena Bioscience). In one case, next-generation sequencing with custom SureSelect library prepa-
ration (Agilent) and MiSeq sequencing (Illumina) were used to assess for variants in the coding regions and 
flanking introns of  CFTR.
Murine and human islet RNA sequencing. Both murine and human islets were hand picked under micro-
scope guidance, washed with PBS, and immediately frozen at –80°C. Islet RNA was extracted (79) using 
the RNAqueous Micro-Total RNA Isolation Kit (Ambion/Invitrogen). Trace contaminating DNA was 
removed with TURBO DNA-free (Ambion/Invitrogen). RNA quality control quantification was performed 
using a Qubit Fluorometer (Invitrogen) and an Agilent 2100 Bioanalyzer. All RNA samples had an RNA 
integrity number ≥6.0. RNA was amplified using the NuGEN Technologies Ovation RNA amplification 
kit, which was optimized for RNA sequencing. Following amplification, the resulting cDNA was sheared 
to an average insert size of  300 bp and used for library preparation. Sequencing was performed using 
standard Illumina methods as described previously (80, 81). Following RNA sequencing, raw reads were 
mapped to reference mouse or human genome as appropriate using TopHat v2.0 (82). Aligned reads were 
imported onto the Avadis NGS data analysis platform (Strand Scientific Intelligence, Bengalor). Reads 
were first filtered on their quality metrics, and then duplicate reads were removed. Normalized gene expres-
sion was quantified using the TMM (trimmed mean of  M values) algorithm (83, 84). The transcriptional 
profile from each sample group was compared by principle component analysis and hierarchal clustering 
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analysis to determine the layout and spread of  the samples. Differential expression between conditions was 
calculated on the basis of  fold change (cutoff  ≥ 2.0), and the P value was estimated by Z-score calculations 
(cutoff  0.05), as determined by the Benjamini-Hochberg false discovery rate method (85). Differential-
ly expressed genes underwent gene set enrichment analysis, gene ontology analysis, and pathway analy-
sis using DAVID and Ingenuity pathway analysis. Sequencing data are available on the Gene Expression 
Omnibus repository (accession GSE110935).
Pancreatic tissue immunochemistry. Prior to islet isolation at the Allegheny Health Network and the Uni-
versity of  Louisville, samples from the pancreatic head, body, and tail were flash frozen and prepared for 
cryosectioning and paraffin sectioning. For cryosections, pancreatic samples were fixed in ice-cold 4% para-
formaldehyde (Electron Microscopy Sciences) in 0.1 M PBS for 3 hours on ice under mild agitation. The 
tissue was washed with 0.1 M PBS and incubated overnight in 30% sucrose at 4°C and embedded in a cry-
omold using Optimal Cutting Temperature compound (Tissue-Tek) and stored at –80°C. For paraffin sec-
tions, the pancreas was fixed in 10% neutral buffered formalin and shipped to Vanderbilt overnight. Upon 
arrival at Vanderbilt, the pancreatic fragments were washed in 70% ethanol and embedded in paraffin.
Five-μm tissue sections were washed in PBS followed by permeabilization with 0.2% Triton X (Bio-
Rad), blocked with normal donkey serum (Jackson ImmunoResearch), incubated overnight at 4°C with 
primary antibodies (Supplemental Table 4), incubated with secondary antibodies (Jackson ImmunoRe-
search), and counterstained with DAPI (Invitrogen) and mounted, as previously described (86). Cryo-
sections were equilibrated to room temperature; paraffin-embedded sections were dewaxed/rehydrated, 
heated in sodium citrate buffer, and rinsed in diH2O prior to staining. TUNEL labeling was performed on 
formalin-fixed/paraffin-embedded sections according to the manufacturer’s instructions (Millipore).
Whole-tissue sections were imaged with an Aperio FL Scanscope (Leica Biosystems). Customized Cyto-
nuclear FL v1.3 cell counting algorithms (Indica Labs) on the HALO platform were used to count islet endo-
crine cell populations (α, β, δ cells), TUNEL+ and insulin+ cells, Ki67+ and insulin+ cells, and CD45+ cells. 
Ratios of islet endocrine cells were determined by dividing the number of the individual cell type (α, β, or 
δ) by the total number of endocrine cells (α, β, and δ). β Cell apoptosis and proliferation were calculated by 
dividing the number of TUNEL+ or Ki67+ and insulin+ cells, respectively, by the total number of insulin+ cells. 
The number of CD45+ cells was divided by the total number of DAPI+ cells to determine the contribution of  
immune cells to the pancreatic tissue. The number of cells counted is summarized in Supplemental Tables 5–8.
H&E labeling and β cell area measurement. Pancreatic sections were stained with H&E or labeled with 
insulin and visualized using a DAB (Vector Laboratories) stain with a hematoxylin counterstain. Images of  
the entire section were captured using an Aperio ScanScope CS (Leica Biosystems). Analysis of  β cell area 
was performed on whole pancreatic sections using customized Tissue Classifiers (Indica Labs) generated 
in Halo (Leica Biosystems). β Cell area was determined by dividing the β cell classified area by the total 
classified area. The classified area is summarized in Supplemental Table 9.
CF islet T cell isolation, stimulation, and intracellular staining. Live hand-picked islets from donor 5 were disso-
ciated and immediately stained with viability dye and T cell markers, which were used to detect T cell popula-
tions by flow cytometry. The gate was set for single cells, viable cells, CD3+ cells, and then for CD4+ and CD8+ 
cells. Cells in the CD8+ gate were then interrogated for CD45RA. CD8+CD45RA+ T cells were interrogated 
for CCR7 and CD62L. CD8+CD45RA+CCR7+CD62L+ T cells were then interrogated for CD27. CD8+C-
D45RA– T cells were interrogated for CCR7 and CD62L, as summarized in Supplemental Figure 14.
Islets from donor 5 were plated on a gel matrix with T cell stimulation and growth factors, and, after 
approximately 10 days, cells growing around islets were collected and expanded as previously described 
(50). T cell lines in early passages (passage 1–3) were left unstimulated or stimulated by adding the cells 
onto wells coated with anti-CD3 (10 μg/ml) overnight at 4°C. Soluble anti-CD28 (2 μg/ml) (BD Biosci-
ences), and GolgiPlug (BD BioSciences) were added to all conditions, and CD107a staining antibody was 
added to all wells and incubated at 37°C for 6 hours. HL-1 media, supplemented with 2 mM L-glutamine, 5 
mM HEPES, and 100 U/ml Penicillin, 100 μg/ml Streptomycin, 0.1 mM of  each nonessential amino acid, 
and 1 mM sodium pyruvate (all from Lonza) and 5% heat-inactivated human male AB serum (Omega 
Scientific), was used in all experiments. Cells were then stained with a viability dye as per manufacturer’s 
instructions (Live Dead Aqua, Thermofisher) and stained for CD3, CD4, and CD8α or CD8β surface 
markers (BD Biosciences). Cells were fixed, permeabilized (BD Cytofix/Cytoperm, BD Biosciences), and 
stained for the intracellular cytokines, IFN-γ and TNF-α. Stained cells were run on a BD LSRII, collecting 
between 30,000–50,000 events, and analyzed with FlowJo software (v.9).
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Statistics. One-way ANOVA followed by Tukey multiple-comparisons test and unpaired 2-tailed Stu-
dent’s t test were used to compare outcomes in mice of  different genotypes. Unpaired 2-tailed Student’s 
t tests were used to compare human samples with and without CF. An ordinary 2-way ANOVA with a 
Sidak’s multiple comparison test was used to compare CF and normal islet hormone secretion during islet 
perifusion. A P value of  less than 0.05 was considered significant.
Study approval. All animal studies were reviewed and approved by the Institutional Animal Care and 
Use Committee (IACUC) at Vanderbilt University Medical Center. Mice were housed and cared for 
according to the Vanderbilt Department of  Animal Care and IACUC/Office of  Animal Welfare Assurance 
standards and guidelines. The Vanderbilt University Institutional Review Board declared that studies on 
deidentified human pancreatic specimens do not qualify as human subject research.
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